Evidence map›Paper›PMID 39861094›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Fabrication and In Vivo Evaluation of In Situ pH-Sensitive Hydrogel of Sonidegib-Invasomes via Intratumoral Delivery for Basal Cell Skin Cancer Management.

Maha M Ghalwash, Amr Gamal Fouad, Nada H Mohammed, Marwa M Nagib, Sherif Faysal Abdelfattah Khalil, Amany Belal, Samar F Miski, Nisreen Khalid Aref Albezrah, Amani Elsayed, Ahmed H E Hassan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maha M GhalwashDepartment of Pharmaceutics and Drug Manufacturing, Faculty of Pharmacy, Modern University for Technology and Information, Cairo 11435, Egypt.
Amr Gamal FouadDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62511, Egypt.ORCID 0000-0002-0082-4160
Nada H MohammedDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Deraya University, Minya 61768, Egypt.
Marwa M NagibDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Misr International University, Cairo 11435, Egypt.ORCID 0000-0002-4508-9497
Sherif Faysal Abdelfattah KhalilPharmacology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef 62511, Egypt.
Amany BelalDepartment of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif 21944, Saudi Arabia.
Samar F MiskiPharmacology and Toxicology Department, College of Pharmacy, Taibah University, Madina 42278, Saudi Arabia.ORCID 0009-0000-2813-245X
Nisreen Khalid Aref AlbezrahDepartment of Obstetric & Gynecology, College of Medicine, Taif University, Taif 21944, Saudi Arabia.
Amani ElsayedDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Taif University, Taif 21944, Saudi Arabia.
Ahmed H E HassanDepartment of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0002-1048-6281
Eun Joo RohChemical and Biological Integrative Research Center, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.ORCID 0000-0002-1368-3133
Shaimaa El-HousinyDepartment of Pharmaceutics and Drug Manufacturing, Faculty of Pharmacy, Modern University for Technology and Information (MTI), Cairo 11435, Egypt.

Funding

KIST Institutional programs from Korea Institute of Science and Technology (KIST) 2E33133National Research Council of Science & Technology (NST) grant by the Korea government (MSIT) CAP23011-100Taif University, Saudi Arabia, TU-DSPP-2024-64
6 · The paper itself

Abstract

BACKGROUND/

objectivesBasal cell skin cancer (BCSC) develops when skin cells proliferate uncontrollably. Sonidegib (SDB) is a therapeutic option for the treatment of BCSC by inhibiting hedgehog signaling. The problems with SDB's low solubility, poor bioavailability, resistance, poor targeting, and first-pass action make it less effective when taken orally. This investigation set out to design an intratumoral in situ pH-sensitive hydrogel of SDB-invasomes (IPHS-INV) that can effectively treat BCSC by improving SDB's bioavailability, sustainability, targeting, and efficacy while also reducing its resistance and undesirable side effects.

methodsNumerous S-INV formulations were developed using Box-Behnken Design Expert and tested before settling on the optimum S-INV formulation. An experimental 7, 12-dimethylbenzanthracene (DMBA) carcinoma rat model was used for in vivo studies of the IPHS-INV formulation after it was combined with chitosan.

resultsPhospholipids (1.72%

conclusionsThese findings support the use of the intratumoral IPHS-INV formulation as an effective strategy for the treatment of BCSC.

Indexed as

basal cell skin cancerbioavailabilitychitosaninvasomessonidegibtargeting

Identifiers

PMID39861094
PMCPMC11769384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.